Author： Davis Brian
Publisher： Adis International
ISSN： 1178-2595
Source： Pharmaceutical Medicine, Vol.23, Iss.1, 2009-01, pp. : 19-24
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Liposomal Drug Formulations: Rationale for Development and What We Can Expect for the Future
By Allen T.M.
Drugs, Vol. 56, Iss. 5, 1998-11 ,pp. :
Access to resources
Recommend
Prevention and Pharmacovigilance: What Should We Do, What Can We Do?
Drug Safety, Vol. 35, Iss. 2, 2012-02 ,pp. :
The diabetic heart - what is to blame and what can we do?
Inpharma, Vol. 1, Iss. 1302, 2001-01 ,pp. :
The Evolution of the Periodic Safety Update Report: Still Fit for Purpose?
Pharmaceutical Medicine, Vol. 24, Iss. 3, 2010-06 ,pp. :
Today's Challenges in Pharmacovigilance: What can we Learn from Epoetins?
Drug Safety, Vol. 34, Iss. 4, 2011-04 ,pp. :